Komori
Semiannual Report3750ADR Biomedical Holdings Inc.Precision instruments

Semiannual Report — FY2026 H1

What ADR Biomedical Holdings Inc. reported for the period from 2026-04-01 to 2027-03-31.

How much it says
56Typical
What moved here
17named for the first time
Its own wording
46terms
Which filing this is
36/ 36newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the interim consolidated accounting period, the domestic mass-production structure for the Celution Cell Therapy Kit was established and full-scale sales began in February 2026, among other factors, resulting in net sales of ¥66 million, up 262.7% year on year, while the operating loss was ¥311 million. The company also raised funds through short-term borrowings under the commitment line, and a material uncertainty related to the going-concern assumption has been identified.

Komori's summary of this document, not the document's own words.
56Typical
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
Magnitude of Change
68
Detailed
Strategic Shift
46
Typical
Capital Movements
50
Typical
Disclosure gaps
15
Almost nothing
Future Commitments
68
Detailed
Change in risk
55
Typical
Financial and capital policy
47
Typical
Product Portfolio
79
Very detailed
Technology position
50
Typical
Confidence in strategic bets
R&D spend1億円Money spent making new things.
Cash left over-4億円Cash from the business, less what went into equipment.
Spent on equipment1百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
ADR Biomedical Holdings Inc. — FY2026 H1 | Komori